Clinical trials: Antipsychotic
Psychotropic Drugs, Psychiatric Drugs
Decreasing Harms and Improving Child Health
The investigators are doing this study because they know from research and talking with caregivers that kids can be on a bunch of medications, and it's hard to keep track of what the medications are for and whether or not they…
- Conditions
- Psychotropic Drugs, Psychiatric Drugs, Children, Shared Decision Making
- Trial name
- NCT07392489
- Testing
- AWARE Shared Decision Making Medication Review
- Where
- 4 sites in United States
- Volunteers
- 31 people
- Sponsor
- Glyn Jones-Elwyn
Schizophrenia, Schizoaffective Disorder
Estradiol as add-on to Antipsychotics
The objective of the study is to evaluate the efficacy of Estradiol patch compared to placebo, as add-on to anti-psychotics in the treatment of women 38 and older with schizophrenia, schizoaffective or schizophreniform disorder.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders
- Trial name
- EST-S-02 (NCT04093518)
- Testing
- Estradiol
- Where
- Moldova
- Volunteers
- 100 people
- Sponsor
- Tangent Data
Schizophrenia
Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Acute Schizophrenia
The purpose of this study is to explore changes in efficacy, cognitive functioning, and safety of flexibly-dosed Brexpiprazole monotherapy in subjects with acute schizophrenia
- Trial name
- NCT02054702
- Testing
- Brexpiprazole, Aripiprazole
- Volunteers
- 97 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Psychotic Disorders
A Study to Assess Safety and Tolerabiltiy Associated With a Switch From Oral Antipsychotic Medications to Long-acting Injectable Risperidone in Patients With Schizophrenia.
The primary purpose of the study is to assess the safety and tolerability of a long-acting injectable formulation of risperidone when switching from an oral antipsychotic in patients with schizophrenia.
- Trial name
- NCT00034775
- Testing
- risperidone
- Volunteers
- 141 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Psychotic Disorders
A Registry of Treatment Adherence for Patients With Schizophrenia
The purpose of the study is to assess demographic, treatment, and outcome data in schizophrenia patients receiving treatment with long-acting injectable, tablet, or liquid formulations of first generation (conventional) or second…
- Trial name
- NCT00283517
- Testing
- antipsychotics
- Volunteers
- 2,046 people
- Sponsor
- Janssen-Cilag, S.A.
Parkinson's Disease Psychosis
Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis
Patients with Parkinson's disease (PD) sometimes experience symptoms affecting their movement, such as slowness, tremor, stiffness, and balance or walking problems.
- Trial name
- C-SAPP (NCT04373317)
- Testing
- Pimavanserin, Quetiapine
- Where
- 24 sites in United States
- Volunteers
- 358 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Metabolic Syndrome
Antipsychotic Medicine and Metabolic Syndrome
The purpose of the study is to determine whether antipsychotic treatment is influence psychiatric patients due to endocrine and metabolic status and a quality of life.
- Trial name
- AMMS1 (NCT00627757)
- Where
- 2 sites in Denmark
- Volunteers
- 100 people
- Sponsor
- Glostrup University Hospital, Copenhagen
Acute Psychotic Episode, Schizophrenia
Non-interventional Study: Real-life Use of Atypical Antipsychotics in Acute Inpatient Management of Schizophrenia
This is an observational study describing the real-life antipsychotic treatment during the hospitalisation of the patients due to acute psychotic episode.
- Trial name
- NCT01491412
- Where
- 14 sites in Hungary, Latvia and 1 more
- Volunteers
- 503 people
- Sponsor
- AstraZeneca
Deprescriptions, Antidepressive Agents
Patient-centred Deprescribing of Psychotropic, Sedative and Anticholinergic Medication in Elderly Patients With Polypharmacy
The PARTNER study is a multicentre, two-arm, pragmatic cluster-randomised trial evaluating the impact of a focused and patient-centred cooperation between general practitioners (GPs) and community pharmacists (PARTNER…
- Conditions
- Deprescriptions, Antidepressive Agents, Antipsychotic Agents, Analgesics, Opioid
- Trial name
- PARTNER (NCT05842928)
- Testing
- PARTNER intervention, Control intervention
- Where
- 3 sites in Germany
- Volunteers
- 352 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Schizophrenia, Psychotic Disorders
Relative Bioavailability of LY03010 Compared to Listed Drug
This is a randomized, multiple-dose, open-label, parallel-group study. Subjects will undergo screening evaluations to determine eligibility within 28 days prior to study drug administration.
- Conditions
- Schizophrenia, Psychotic Disorders, Mood Disorders, Schizophrenia Spectrum
- Trial name
- NCT04922593
- Testing
- LY03010; paliperidone palmitate, INVEGA SUSTENNA
- Where
- 9 sites in United States
- Volunteers
- 281 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Schizophrenia
Development of Population Norms of the Computerized Neuropsychological Assessment for Effectiveness of the Antipsychotic Treatment in Schizophrenia
Schizophrenia affects cognition, emotion, and behavior. Neuropsychological assessment enables a better understanding of antipsychotic effectiveness and the brain processes, underlying cognitive functioning in schizophrenia.
- Trial name
- NCT00789906
- Where
- Israel
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- BeerYaakov Mental Health Center
Schizophrenia
Reboxetine and Citalopram as an Adjunct Treatment to Second Generation Antipsychotics in the Treatment of Negative Symptoms of Schizophrenia
Main objective: To assess the efficacy of two antidepressants of different pharmacological families: citalopram (Selective serotonin reuptake inhibitors, SSRI) and reboxetine (Norepinephrine Reuptake inhibitor, NRI) as adjunct…
- Trial name
- NCT01300364
- Testing
- Reboxetine, citalopram (SSRI)
- Where
- Spain
- Volunteers
- 249 people
- Sponsor
- Fundació Sant Joan de Déu
Antipsychotics in Palliative Care
Use of Antipsychotics in Palliative Care (NEUROPAL)
There are not lots of recommendations for the use of antipsychotics in palliative care. The National Agency for Accreditation and Evaluation in Health (ANAES) and the French Society for Accompaniment and Palliative Care, in 2002…
- Trial name
- NEUROPAL (NCT03155685)
- Volunteers
- 100 people
- Sponsor
- University Hospital, Caen
Weight Gain
Improving Metabolic Parameters of Antipsychotic Child Treatment With Ziprasidone, Aripiprazole, and Clozapine
The purpose of this study is to evaluate the relative risks and benefits of two approaches to the control of weight gain and other negative side effects in children and adolescents on 2nd generation antipsychotics (SGA): Healthy…
- Trial name
- ZAC (NCT00617058)
- Testing
- metformin, healthy lifestyle intervention
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of North Carolina, Chapel Hill
Psychosis, Metabolic Syndrome
Evaluating the Effects of Adjunctive Aripiprazole on Weight and Metabolic Outcomes in Females
Patients with psychiatric disorders, including depression, anxiety, and schizophrenia, often require antipsychotic medications for symptom management.
- Conditions
- Psychosis, Metabolic Syndrome, Weight Gain
- Trial name
- NCT06590298
- Testing
- Adjunctive Aripiprazole for improving Weight and Metabolic Outcomes in Females
- Volunteers
- 600 people
- Sponsor
- Universiti Putra Malaysia
Schizophrenia, Negative Symptoms in Schizophrenia
A Study on the Efficacy of Agomelatine Combined With Antipsychotics to Treat Negative Symptoms in Schizophrenia
This study is a prospective, multicenter, controlled, real world study. Patients will be randomly enrolled into the test group and the control group at a ratio of 1:1 during the screening period.
- Trial name
- NCT05646264
- Testing
- Agomelatine
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Shanghai Mental Health Center
Metabolic Evaluation, Cardiac Complications
Metabolic and Clinical Effect of Alpha-lipoic Acid Administration in Schizophrenic Subjects
The therapeutic use of ALA in schizophrenia has recently been investigated in human populations. A case series explored the effiacy of ALA as a novel agent to treat antipsychotic-induced obesity, at a dose of 1200 mg/d (range…
- Trial name
- NCT06787781
- Testing
- Alpha Lipoic Acid
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- University of Messina
Psychotic Disorder
Deprescribing Antipsychotics: a Multiple Case Study
The literature on antipsychotic deprescribing highlights the difficulty in establishing a clear consensus on the most optimal strategy due to the diversity of clinical situations encountered in daily practice: who should be…
- Trial name
- DEPRESC (NCT07343193)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Strasbourg, France
Psychotic Disorders
Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics
This study will test the effectiveness of two different treatments for children and adolescents who have gained weight on their antipsychotic medications.
- Trial name
- IMPACT (NCT00806234)
- Testing
- Aripiprazole or Perphenazine, Metformin, Olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, or olanzapine/fluoxetine
- Where
- 4 sites in United States
- Volunteers
- 127 people
- Sponsor
- Johns Hopkins University
Psychotic Disorders, Schizophrenia
Study of the Effect of Dosing on Clozapine Levels
The objectives of this 15-day study are: 1. To compare steady-state trough plasma concentrations of clozapine and its metabolite norclozapine when given once daily and twice daily (at the same total daily dose) 2.
- Trial name
- PK-CLZ (NCT02286206)
- Testing
- Clozapine
- Where
- Canada
- Sponsor
- University of British Columbia